Abstract Purpose: Mitogen-activated protein 4 kinase 4 (MAP4K4) is a serine/threonine kinase and belongs to the mammalian STE20/MAP4K family. Recent studies have shown that MAP4K4 is overexpressed in many types of human cancer and cancer cell lines. MAP4K4 plays an important role in transformation, invasiveness, adhesion, and cell migration. However, the expression of MAP4K4 and its significance in pancreatic ductal adenocarcinoma (PDA) has not been studied. Experimental Design: We examined the expression of MAP4K4 by immunohistochemistry using tissue microarrays consisting of 66 stage II PDA and their paired benign pancreatic tissue. The staining results were categorized as MAP4K4-H or MAP4K4-L. The results were correlated with clinicopathologic features and patient survival. Results: MAP4K4 was overexpressed (MAP4K4-H) in 30 of 66 (46%) PDAs and was higher than the paired benign pancreatic tissue samples (19%; P = 0.002). The median overall and recurrence-free survival for patients with MAP4K4-H PDAs were 19.5 and 9.3 months, respectively, compared with 65.2 and 28.8 months for patients with MAP4K4-L tumor (P = 0.02 and 0.0005, log-rank test). MAP4K4 expression was associated with poor overall and recurrence-free survival in univariate analysis (P = 0.02 and 0.001). In multivariate analysis, MAP4K4 expression significantly correlated with overall and recurrence-free survival (P = 0.025 and 0.004) independent of age, tumor size, differentiation, and stage. MAP4K4 expression was also associated with higher frequency of recurrence/metastasis, larger tumor size, and increased number of positive lymph nodes (P < 0.05).
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer death in the United States, preceded only by lung, colon, and breast cancers (1) . Pancreatic cancer has one of the highest mortality rates, and virtually all patients with PDA die from it (2) . Even for early stages of resectable PDAs, the tumor commonly recurs, with the most common sites of recurrence being the liver, lung, peritoneal cavity, and pancreatic surgery bed. Studies have shown that multiple genes are frequently altered in PDAs, including activation of the K-ras oncogene by point mutation and inactivation of p16, SMAD4/ DPC4, and p53 tumor suppressor genes (3 -7) . Although the genetic profile for pancreatic cancer is emerging, the role of specific genetic alterations involved in the aggressive growth and metastasis of PDA is unclear.
Mitogen-activated protein 4 kinase 4 (MAP4K4; also called hepatocyte progenitor kinase-like/germinal center kinase-like kinase) is a serine/threonine kinase and belongs to the mammalian STE20/MAP4K family. Recent studies have shown that MAP4K4 is overexpressed in many types of human cancer cell lines and tumors compared with normal tissue (8) . Dominantnegative mutant of MAP4K4 suppresses the Ras-induced transformation in NIH3T3 cells and rat intestinal epithelial cells (8) . In addition, expression of inactive mutant MAP4K4 inhibits the anchorage-independent cell growth and hepatocyte growth factor-stimulated epithelial cell invasion (8) . Furthermore, knockdown of MAP4K4 mRNA by small interfering RNA inhibits the tumor cell migration and invasion of ovarian cancer, breast cancer, prostate cancer, and malignant melanoma (9) . These studies show that MAP4K4 plays an important role in transformation, cell migration, and invasiveness of cancer cells (9, 10) . The prognostic value of MAP4K4 expression in PDA has, however, not been studied, because majority of the patients with surgically resectable PDAs have stage II disease and little is known about the prognosis in this group of patients. In this study, we examined the expression of MAP4K4 in 66 pancreaticoduodenectomy specimens of stage II PDA and their paired nonneoplastic pancreatic ductal epithelial cells. Using univariate and multivariate analysis, we correlated the expression level of MAP4K4 with survival and other clinicopathologic features in patients with stage II PDA.
Materials and Methods
Case selection. We constructed tissue microarrays using formalinfixed, paraffin-embedded archival tissue samples of 66 specimens from patients with stage II PDAs who had undergone pancreaticoduodenectomy at The University of Texas M. D. Anderson Cancer Center between 1990 and 2005 and had not received any preoperative chemotherapy and/or radiation therapy. Patients who received preoperative chemotherapy and/or radiation and who died from postoperative complications were excluded. Our study group consisted of 44 male patients and 22 female patients with a median age at time of surgery of 63.7 years (range, 39.8-79.9 years). This study was approved by the Institutional Review Board of The University of Texas M. D. Anderson Cancer Center.
Tissue microarrays. To construct the tissue microarrays used in this study, formalin-fixed, paraffin-embedded archival tissue blocks and their matching H&E-stained slides were retrieved, reviewed, and screened for representative tumor regions and nonneoplastic pancreatic parenchyma by a gastrointestinal pathologist (H.W.). For each patient, two cores of tumor and two cores of paired benign pancreatic tissue were sampled from representative areas using a 1.0 mm punch. The tissue microarrays were constructed with a tissue microarrayer (Beecher Instruments) as described previously (11) .
Immunohistochemical analysis for MAP4K4. Immunohistochemical staining for MAP4K4 was done on 4 Am unstained sections from the tissue microarray blocks using a rabbit polyclonal antibody against MAP4K4 (1:250 dilution), which has been characterized previously (12) . To retrieve the antigenicity, the tissue sections were treated at 100jC in a steamer containing 10 mmol citrate buffer (pH 6.0) for 60 min. The sections were then immersed in methanol containing 0.3% hydrogen peroxidase for 20 min to block the endogenous peroxidase activity and were incubated in 2.5% blocking serum to reduce nonspecific binding. Sections were incubated for 90 min at 37jC with primary anti-MAP4K4 at a 1:250 dilution. Standard avidin-biotin immunohistochemical analysis of the sections was done according to the manufacturer's recommendations (Vector Laboratories). Diaminobenzidine was used as a chromogen, and hematoxylin was used for counterstaining. The staining results were evaluated independently by two gastrointestinal pathologists (J.J.L. and H.W.) to determine the average percentage of positive cells in two cores. Using the median value of 10% as a cutoff, high expression of MAP4K4 (MAP4K4-H) was defined as cytoplasmic staining of z10% of the tumor cells and low expression of MAP4K4 (MAP4K4-L) was defined as cytoplasmic staining of <10% of the tumor cells or no cytoplasmic staining as reported previously (13) .
Statistical analysis. The Fisher's exact tests were used to compare categorical data. Overall survival and recurrence-free probability curves were constructed using the Kaplan-Meier method, and the log-rank test was used to evaluate the statistical significance of differences. The patients' follow-up information through September 2006 was extracted from the prospectively maintained institutional pancreatic cancer database managed in the Department of Surgical Oncology and, if necessary, updated by review of the U.S. Social Security Index. The recurrence information was updated every time a patient came to the clinic/institution for a follow-up visit. Recurrence-free survival was calculated as the time from the date of surgery to the date of first recurrence after surgery (in patients with recurrence) or to the date of last follow-up (in patients without recurrence). The overall survival was calculated as the time from the date of diagnosis to the date of death or the date of last follow-up (if death did not occur).
The prognostic significance of clinical and pathologic characteristics was determined using univariate Cox regression analysis. Cox proportional hazards models were fitted for multivariate analysis. After interactions between variables were examined, a backward stepwise procedure was used to derive the best-fitting model. Statistical analysis was done using Statistical Package for Social Sciences software (for Windows 12.0; SPSS). We used a two-sided significance level of 0.05 for all statistical analyses.
Results
Thirty of 66 (46%) of stage II PDAs were MAP4K4-H. Among these 66 cases, the paired benign pancreatic tissue samples from 62 cases were available. Twelve (19%) of them (11 of 48 chronic pancreatitis samples and 1 of 14 normal pancreatic tissue sample) were MAP4K4-H, which was significantly lower than that in PDAs (P = 0.002; Table 1 ). PDAs and the proliferating pancreatic ductules in chronic pancreatitis showed cytoplasmic staining for MAP4K4 (Fig. 1) . The acinar cells or islet cells were negative for MAP4K4.
Clinicopathologic characteristics of the study population are summarized in Table 2 . According to the WHO classification standards, 10 (15%) cases were well-differentiated, 41 (62%) 
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moderately differentiated, and 15 (23%) poorly differentiated adenocarcinoma. Of the 66 cases, 52 (79%) had R0 resection (defined as all surgical margins negative microscopically), 14 patients had R1 resection, and no patients had a grossly positive margin of resection. Fifty-two (79%) patients underwent postoperative therapy due to recurrence or metastasis. At the time of last follow-up, 48 patients had died of disease and 18 patients were alive.
There were significant differences in tumor size and the frequencies of recurrence/distant metastasis after resection between MAP4K4-H and MAP4K4-L groups (Table 2) . Recurrence/distant metastasis was present in 83% (25 of 30) of the patients with MAP4K4-H tumors compared with 58% (21 of 36) of patients with MAP4K4-L PDAs (P = 0.03). High levels of MAP4K4 expression were also associated with larger tumor size (P = 0.01). Although there was no significant difference in the frequencies of lymph node metastasis between MAP4K4-H and MAP4K4-L tumors, the average number of positive lymph nodes in pancreaticoduodenectomy specimens was 3.9 F 4.3 in MAP4K4-H group compared with 1.5 F 1.8 in MAP4K4-L (P = 0.003). There was no difference in the total number of lymph nodes examined between these two groups (20.0 F 9.2 in MAP4K4-H group versus 19.4 F 7.3 for MAP4K4-L group; P = 0.80). No association was found between MAP4K4 expression and other clinicopathologic features (Table 3) .
After pancreaticoduodenectomy, the median and mean follow-up of the patients in this study were 22.9 and 38.0 months, respectively. No patients were lost to follow-up. The patients whose tumors were MAP4K4-H had a worse prognosis. The median overall survival was 19.5 F 2.9 months for patients with MAP4K4-H PDAs compared with 65.2 F 19.4 months for patients whose tumors were MAP4K4-L (P = 0.02, log-rank test; Fig. 2 ). The median recurrence-free survival were 9.3 F 1.8 and 28.8 F 18.0 months for patients with MAP4K4-H and MAP4K4-L PDAs, respectively (P = 0.0005, log-rank test; Fig. 2 ).
High levels of MAP4K4 expression were associated with poor overall and recurrence-free survival in univariate analysis (P = 0.025 and 0.001, respectively; Table 2 ). In multivariate analysis, MAP4K4 expression was a predictor of overall and recurrence-free survival (P = 0.025 and 0.004) independent of age, tumor size, differentiation, and lymph node status/stage (Table 4) . 
Discussion
In this study, we examined the MAP4K4 expression in 66 stage II PDAs and their matched benign pancreatic tissue samples. We found that MAP4K4 was overexpressed in 46% of the stage II PDAs compared with 19% of the matched benign pancreatic tissue samples. MAP4K4 overexpression was associated with higher frequency of distant metastasis/recurrence after pancreaticoduodenectomy, larger tumor size, and increased number of positive lymph nodes in patients with stage II PDAs. Furthermore, MAP4K4 expression was associated with poor overall and recurrence-free survival and was a prognostic factor for patients with stage II PDA.
MAP4K4 belongs to the mammalian STE20/MAP4K family. MAP4K4 mRNA has been shown to be overexpressed in several human malignancies compared with normal control tissue (8) . In addition, MAP4K4 has been shown to be involved in cell migration and invasion in a variety of tumor cell lines, including malignant melanoma, ovarian, breast, and prostate cancers (9) . Knockdown of MAP4K4 mRNA using small interfering RNA in these tumor cell lines inhibits the cancer cell migration and invasion (9) . In the presence of hepatocyte growth factor, overexpression of MAP4K4 increases the invasive ability of rat intestinal epithelial cells (8) . The promigratory effect of MAP4K4 is mediated through the c-Jun NH 2 -terminal kinase, which plays critical role in stress responses, cell proliferation, apoptosis, and tumorigenesis (9, 14 -18) . Although these studies clearly show the role of MAP4K4 in cancer cell migration and invasion, the role of MAP4K4 in pancreatic cancer has not been examined. Our study showed that 46% of stage II PDAs overexpressed MAP4K4 protein. It was interesting that MAP4K4 was also overexpressed in 23% of pancreatic ductules in chronic pancreatitis but only in 7% of pancreatic ducts from normal pancreas, suggesting that MAP4K4 may play a role in chronic pancreatitis and benign pancreatic ductular proliferation. In our study, MAP4K4 overexpression correlated with larger tumor size, increased number of positive lymph nodes, and recurrence/metastasis of PDAs. In addition, we found that high levels of MAP4K4 expression were present in 3 of 3 patients with stage IV PDAs but not in the two patients with stage I PDAs (data not shown). These findings support the role of MAP4K4 in the invasion/metastasis of pancreatic cancer. The ability to inhibit MAP4K4 and its downstream signaling pathways may offer new potential avenues for the development of novel therapeutic strategies.
In this study, we showed that MAP4K4 expression in stage II PDAs correlates with poor outcome. MAP4K4 expression correlated strongly with poor overall and recurrence-free survival in univariate analysis and was a prognostic factor associated with worse prognosis in multivariate analysis. Because most patients with PDA present with locally advanced disease, other secondary prognostic factors, particularly MAP4K4, may be of use. Previous studies have shown potential prognostic markers for PDAs, including loss of SMAD4 expression (19, 20) , copy number of chromosome 17 (21) , activated Akt and Erk levels (22) . Tascilar et al. examined SMAD4 protein expression in 249 patients who underwent pancreaticoduodenectomy for PDA and found that SMAD4 protein expression is a prognostic factor independent of other clinicopathologic parameters (20) . It would be interesting to compare the prognostic value of MAP4K4 with these reported markers in future studies for patient stratification in clinical trials.
In conclusion, our results showed that MAP4K4 was overexpressed in stage II PDAs. High levels of MAP4K4 expression in stage II PDAs were associated with poor prognosis and were a prognostic marker for stage II PDAs. Further studies are needed to determine whether MAP4K4 expression may be served as a potential target for directed therapy in PDA.
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